Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
951395-08-7
Purity
95%
Tafamidis stabilizes transthyretin tetramers, reducing the amount of monomers available for amyloidogenesis. Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
Properties
Name
Tafamidis meglumine
Smiles
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C=1C=CC=2N=C(OC2C1)C=3C=C(Cl)C=C(Cl)C3
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
SDS
6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine | tafamidis meglumine
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$37
2 mg
$39
5 mg
$41
10 mg
$43
15 mg
$45
20 mg
$48
25 mg
$53
30 mg
$55
35 mg
$58
40 mg
$60
45 mg
$63
50 mg
$65
75 mg
$68
100 mg
$POA
Quantity
1
Total amount
$ 41
6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine | tafamidis meglumine
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
CAS:594839-88-0
0